IGM Biosciences, Inc. (IGMS) |
|
22.48 0.49 (2.23%)
|
01-27 16:00 |
|
Open: |
21.89 |
Pre. Close: |
21.99 |
|
High:
|
22.65 |
Low:
|
21.79 |
|
Volume:
|
119,222 |
Market Cap:
|
963(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:45:26 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 32.61 One year: 38.08 |
| Support: |
Support1: 20.12 Support2: 15.3 |
| Resistance: |
Resistance1: 27.92 Resistance2: 32.61 |
| Pivot: |
22.48  |
| Moving Average: |
MA(5): 22.94 MA(20): 21.11
MA(100): 20.39 MA(250): 19.13 |
| MACD: |
MACD(12,26): 1.1 Signal(9): 1 |
| Stochastic oscillator: |
%K(14,3): 51.3 %D(3): 55.7 |
| RSI: |
RSI(14): 54.7 |
| 52-week: |
High: 35.97 Low: 12.67 |
| Average Vol(K): |
3-Month: 250 (K) 10-Days: 177 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IGMS ] has closed above bottom band by 49.9%. Bollinger Bands are 59.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
22.66 - 22.8 |
22.8 - 22.93 |
|
Low:
|
21.47 - 21.63 |
21.63 - 21.78 |
|
Close:
|
22.23 - 22.47 |
22.47 - 22.7 |
|
Company Description |
|
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. |
Headline News |
Thu, 26 Jan 2023
Vacation Rental Platforms Market Size [2023-2028] | is Projected to ... - Digital Journal
Wed, 25 Jan 2023
Does IGM Biosciences Inc (IGMS) Have What it Takes to be in Your Portfolio Wednesday? - InvestorsObserver
Tue, 17 Jan 2023
IGM Biosciences Says First Patient Dosed in Trial for Potential Solid Tumor Treatment - Marketscreener.com
Mon, 16 Jan 2023
Medivir to present at the Redeye Fight Cancer Day - Jan 16, 2023 - BioSpace
Mon, 16 Jan 2023
Medivir to present at the Redeye Fight Cancer Day - InvestorsObserver
Thu, 12 Jan 2023
Is IGM Biosciences Inc (IGMS) Stock About to Get Hot Thursday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
29 (M) |
|
% Held by Insiders
|
8.91e+006 (%) |
|
% Held by Institutions
|
38.4 (%) |
|
Shares Short
|
3,560 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.1689e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-31 |
|
Return on Assets (ttm)
|
904.1 |
|
Return on Equity (ttm)
|
-31.9 |
|
Qtrly Rev. Growth
|
697000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-6.94 |
|
Qtrly Earnings Growth
|
-5.6 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-3 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.91 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
3.64e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
